Intravitreal ganciclovir for cytomegalovirus retinitis in patients with AIDS.
OBJECTIVE
To assess the evolution of cytomegalovirus (CMV) retinitis and evaluate the possible complications associated with the use of intravitreal injections to treat this disease.


METHODS
A nonrandomized, retrospective study with case series was performed. The study took place over 34 months.


METHODS
The study included patients with AIDS who developed CMV retinitis, and who were treated in the hospital, as outpatients, or both.


METHODS
Twelve patients with AIDS and CMV retinitis diagnosed between June 1990 through April 1993 were included in the study. MAIN PATIENT PARAMETERS AND OUTCOME MEASURES: For each patient, the following data were recorded: age, risk factors, other systemic findings, dates of AIDS and CMV retinitis diagnoses, stage of AIDS, extent of the retinitis, CD4 lymphocyte count at the time of diagnosis of retinitis, visual acuity, clinical evolution of the ocular infection, therapy, complications caused by the treatment, development on nonocular CMV, and the use of zidovudine or didanosine during the study period.


RESULTS
Vision improved or remained stable in nine patients and worsened in three. Two patients developed optic neuritis. The retinitis progressed to the other eye in only one of the eight patients who had unilateral involvement. The rate of relapse with maintenance therapy was 8.3% (n = 1) within the first 8 weeks. Treatment was well tolerated. There was no evidence of toxicity after a total of 226 intravitreal ganciclovir injections. All patients were able to tolerate zidovudine or didanosine concomitantly with intravitreal ganciclovir.


CONCLUSIONS
Intravitreal ganciclovir appears to be an effective alternate to systemic ganciclovir in patients with severe neutropenia and in patients who choose to continue receiving systemic zidovudine or didanosine. Early treatment and long-term maintenance therapy is essential for preserving sight.
Montero
M C
MC
University Hospital Virgen del Rocío, Sevilla, Spain.
Pastor
M
M
Buenestado
C
C
Lluch
A
A
Atienza
M
M
D017088:AIDS-Related Opportunistic Infections / Q000150:complications / Q000188:drug therapy*; D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage*; D017726:Cytomegalovirus Retinitis / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D016049:Didanosine / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D005260:Female; D017245:Foscarnet / Q000008:administration & dosage; D015774:Ganciclovir / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D016896:Treatment Outcome; D014822:Vitreous Body; D015215:Zidovudine / Q000008:administration & dosage
D000998:Antiviral Agents; D017245:Foscarnet; D015215:Zidovudine; D016049:Didanosine; D015774:Ganciclovir